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Abstract
Background: Bitter taste receptors are genetically diverse, so children likely vary in sensitivity to the “bad” taste of
some pediatric formulations. Based on prior results that variation in a bitter taste receptor gene, TAS2R38, was
related to solid (pill) formulation usage, we investigated whether this variation related to liquid formulation
usage and young children’s reports of past experiences with medicines and whether maternal reports of these past
experiences were concordant with those of their children.
Methods: We conducted retrospective interviews of 172 children 3 to 10 years old and their mothers (N = 130)
separately in a clinical research setting about issues related to medication usage. Children were genotyped for
the TASR38 variant A49P (alanine to proline at position 49). Children’s responses were compared with their TAS2R38
genotype and with maternal reports.
Results: Children (>4 years) reported rejecting medication primarily because of taste complaints, and those
with at least one sensitive TAS2R38 allele (AP or PP genotype) were more likely to report rejecting liquid
medications than were those without a taster allele (AA genotype; χ2 = 5.72, df = 1, p = 0.02). Children’s and
mothers’ reports of the children’s past problems with medication were in concordance (p = 0.03).
Conclusions: Individual differences in taste responses to medications highlight the need to consider children’s
genetic variation and their own perceptions when developing formulations acceptable to the pediatric palate.
Pediatric trials could systematically collect valid information directly from children and from their caregivers
regarding palatability (rejection) issues, providing data to develop well-accepted pediatric formulations that
effectively treat illnesses for all children.
Trial Registration: Clinicaltrials.gov protocol registration system (NCT01407939). Registered 19 July 2011.
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Background
Most children, at some point in their lives, are given
medicine to treat an illness or disease, and some will re-
ject it. A variety of factors, including the child’s age,
body size, mechanics of swallowing [1], and taste prefer-
ences [2] affect acceptance of medicine. While factors
inherent to the child cannot be changed, the formulation
of the medicine can be. Pediatric medications come in
several oral formulations (liquid, tablet or pill) and con-
tain flavors and excipients (e.g., sweeteners), which can
cater to the pediatric palate [2]. However, while solid oral
dosage forms (pills) have the advantage of encapsulating
the taste of active pharmaceutical ingredients (so pills are
less bitter and less irritating than liquids), some children
have difficulty swallowing them, and fixed doses are often
impractical for body-weight-based dosages. Moreover,
many drugs have not been clinically tested in infants and
children and thus lack appropriate pediatric formulations
[3, 4], leading many to recognize the general need for bet-
ter medicines for children worldwide.
Children cannot benefit from medicines they will not
take [5]. “Taste” is often cited as a primary issue for
noncompliance [5], based on a variety of questionnaire-
based survey and phone interview studies of parents
[6–8], physicians [9, 10], and health care personnel [9],
but studies rarely asked children directly about their
likes and dislikes of medications (but see ref. [11]), and
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few have determined whether mothers’ reports about
their children’s acceptance or rejection of the medicine
match those of their children. In the present study, we
used a clinical research setting to separately interview
directly both children and their mothers. We probed
whether children can respond to open-ended questions
about past experiences with medicines to determine
whether their reports are concordant with those of
their mothers. We also genotyped the children for a
known bitter taste receptor gene but acknowledge that
bitter taste is not the sole culprit of the type of bad
taste of medicines, since many drugs can irritate the
throat or mouth and contain unpleasant volatiles [2].
Because not all children reject medicines, genetic
variation in taste receptor biology may explain some of
these individual differences. During the past decade, re-
search has reported 25 members in the TAS2R family
of bitter-taste receptors [12]. These receptors are se-
lectively sensitive to particular compounds and are gen-
etically extremely diverse [12]. The most studied bitter
taste receptor gene, TAS2R38, has several forms [13, 14].
People who are homozygous for the insensitive form (AA)
typically cannot taste the bitterness of its ligands, includ-
ing a medication to treat hyperthyroidism, propylthioura-
cil (PTU or PROP) [13, 14]. The phenotype–genotype
relationship for this receptor varies with age such that chil-
dren with the bitter-sensitive genotypes (AP, PP) are more
sensitive to the bitter taste of this medicine than are their
parents with the same genotypes [15, 16]. Further, recent
evidence suggests that variation in bitter taste receptor
genotype may be related to medication acceptance among
children. That is, a retrospective analysis found that
children with bitter-sensitive (homozygous PP and hetero-
zygous AP) TAS2R38 genotypes were more likely to have
taken medication in a solid formulation than were children
with the bitter-insensitive (AA) genotype [17], perhaps
because their bitter sensitivity makes them more motivated
to take pills or tablets.
In this study, we queried a large and diverse group of
children (N = 172) and their mothers about past experi-
ences with medicine focusing on liquid formulations
since this is the most frequently experienced formulation
type taken by children of this young age group. Children
were genotyped for the TAS2R38 A49P allele to test the
hypothesis that variation in this bitter taste receptor
gene may explain individual differences in some “taste”
issues encountered in using liquid formulations and
their reports of past experiences with medicines.
Methods
Participants
Participants were healthy 3- to 10-year-old children and
their mothers who participated in two research studies
on bitter taste perception [15, 18]. During the telephone
interview, the mothers were given detailed descriptions of
the procedures for the present study but were not told the
goals of the study or hypotheses being tested. Women
who were diabetic, pregnant, or lactating were not eligible,
and pregnancy tests were conducted on the day of testing
to confirm they were not pregnant. Children who were on
any medications that may alter taste sensitivity were ex-
cluded from the studies. All children were reported to be
healthy by their mothers.
Ethics committee approval
All procedures were approved by the Office of Regulatory
Affairs at the University of Pennsylvania, Protocol
Number 809789. Written informed consent was obtained
from a parent of each child, and assent was obtained from
each child 7 years of age and older. The study was regis-
tered on ClinicalTrials.gov Protocol Registration System
(NCT01407939).
Procedures
Mothers and children were queried separately in private
testing rooms. Mothers completed questionnaires re-
garding demographics and race (assigned per US Census
categories) and were asked individually about their child’s
overall medication history, including types of formulations
(e.g., liquids, drops, pills or tablets, nasal sprays), flavor
preferences, and past problems. Children were also
asked directly and privately (in a separate testing room
without the presence of the mother) about their past
experiences of taking medicines: whether they were
ever given medicine to drink, chew, or swallow; if so,
whether there were any medicines they would not take;
and if so, why they refused.
Genotyping methods
A saliva sample was collected and genomic DNA was
extracted from it following the directions of the manu-
facturer (Oragene, DNA Genotek, and Canada). The
TAS2R38 A49P alleles (rs713598; accession no.
AF494231) were genotyped using dye-based primers
and probes (Life Technologies, Grand Island, New York).
Children were identified as bitter-insensitive homozygous
(AA), bitter-sensitive homozygous (PP), or heterozygous
(AP) [13]. Although there are three common variant sites
in this gene, we chose to group children by the first
one (A49P, rs713598) because it explains most of the
individual differences in the taste response [16, 19]
and is a proxy for other variants due to linkage dis-
equilibrium [20]. Genotyping quality steps included
assaying known control samples, assaying 10 % of
samples in duplicate, and establishing that genotypes
were in Hardy-Weinberg equilibrium.
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Statistical analyses
All analyses were conducted using Statistica (version 12;
StatSoft, USA). ANOVAs determined whether children
grouped by formulation acceptance varied by age. Nonpara-
metric analyses assessed whether there were associations 1)
between TAS2R38 genotype and reported problems with
liquid medications and 2) between responses of children
and their mothers. Genetic analyses were conducted as-
suming a dominant model [13, 16, 18] in which children
with one or two bitter sensitive alleles were grouped and
compared to children who were homozygous for the in-
sensitive allele. Summary statistics are means ± SEM or per-
centage of group.
Results
The mothers averaged 33.9 ± 0.7 years old (N = 130),
and the children (N = 172) were between the ages of 3
and 10 years. Included in the sample were 94 single-
tons, 31 sibling dyads, 4 sibling triads, and 1 sibling
tetrad. As shown in Table 1, children’s race/ethnicity,
family yearly income, and mothers' highest education
level, based on maternal reports, reflected the racial and
socioeconomic diversity of the Philadelphia area [21].
Duplicate genotyping assay results matched in every case
and genotypes were in Hardy-Weinberg equilibrium
[χ2(2)=2.45, p = 0.29]. Genotypes of three children could
not be obtained even after multiple attempts.
Mothers reported that the children had last been given
medication within the past 6.1 ± 0.5 months (range: <1-
36 months): cold and pain remedies (98.3 %), antibiotics
(52.9 %), antihistamines (26.2 %), anti-asthmatics (11.0 %),
gastrointestinal (4.7 %), antifungal (4.1 %), and psychiatric
(2.9 %). All had prior experience with liquid formulations.
Cherry, bubble gum, and grape were reported to be the
children’s favorite flavorings. Regardless of their child’s
age, most mothers preferred pediatric liquid formulations
(63.4 %), followed by chewable tablet (19.8 %) or gummy
(9.3 %) formulation (Table 2).
Not all children answered the questions. Of the 172
children, 19 (11.0 %) did not respond when asked if they
had ever refused medication (Table 1). These 19 children
were significantly younger (6.2 ± 0.4 years) than the 153
children who did respond to the questions (8.0 ±
0.1 years; F(1, 170) = 18.69; p < 0.0001). The vast major-
ity of the non-responders had bitter sensitive genotypes
(84.2 % were AP/PP; 15.8 % were AA). None of the chil-
dren who were younger than 4 years of age responded to
the questions.
Table 1 Subject demographics
Measure Data
Children (N = 172):
Sex (girls, boys) 97 girls, 75 boys
Age, years [mean ± SEM (n)] 7.8 ± 0.1 (172)
Race/ethnicity [% (n)]
White 12.8 % (22/172)
Black 56.4 % (97/172)
Hispanic 14.5 % (25/172)
Asian 1.2 % (2/172)
Other/more than one race 15.1 % (26/172)
TAS2R38, A49P genotype [ % (n)]a
AA 29.6 % (50/169)
AP 45.6 % (77/169)
PP 24.8 % (42/169)
No. children who did not answer questions
regarding medication usage [% (n)]
11 % (19/172)
Non-Responders’ Genotype
AA 15.8 % (3/19)
AP/ PP 84.2 % (16/19)
Mothers (N = 130)b:
Age, years [mean ± SEM (n)] 33.9 ± 0.7 (130)
Family Yearly Income, [% (n)]
< $35,000 62.3 % (81/130)
$35,000–$75,000 26.2 % (34/130)
> $75,000 11.5 % (15/130)
Highest Education Level, college graduate, [% (n)] 48.5 % (63/130)
aData from 3 children were refractory to genotyping
bMothers of 94 singletons, 31 sibling pairs, 4 sibling triads, and 1 sibling tetrad
Table 2 Children’s medication history as reported by Mothersa
Questions % (n/N)
Child has taken medications 100 % (172/172)
Liquid drops or liquids 100 % (172/172)
Chewable 34.3 % (59/172)
Nasal sprays 18.0 % (31/172)
Pills or tablets 19.8 % (34/172)
Child had problems taking medication 48.3 % (83/172)
Liquid drops or liquids 41.9 % (72/172)
Chewable 16.1 % (9/56)b
Nasal sprays 45.2 % (14/31)
Pills or tablets 32.4 % (11/34)
Preferred pediatric formulation
Liquid 63.4 % (109/172)
Chewable tablet 19.8 % (34/172)
Gummy 9.3 % (16/172)
Pill/tablet 2.3 % (4/172)
Strips 1.1 % (2/172)
No preference/other 4.1 % (7/172)
aIf mother had multiple children in the study, she reported which formulation
she most preferred for her children
bData missing for three mothers for this entry
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Of the 153 children who responded to the questions,
89 (58.2 %) reported refusing to take medications, and
86 (96.6 % of those who reported refusal) responded
when asked why they had refused. We found mother-
child concordance (N = 153 dyads) in reports of past
problems taking medications (χ2 = 4.96, df = 1, p = 0.03).
About half of the mothers (48.3 %; Table 2) and children
(58.2 %; Table 3) reported such problems. The primary
reason children gave for rejecting medicine was “taste”
complaints (Table 3).
Reports of medication compliance were related to bit-
ter receptor genotype. More children with at least one
sensitive TAS2R38 allele (AP, N = 77; PP, N = 42) re-
ported having problems accepting liquid formulations
(48 % with AP/PP, N = 57/119) than did those with no
bitter alleles (28 % with AA, N = 14/50; χ2 = 5.72, df = 1,
p = 0.02). Of those children who had been offered pills
(N = 34), there was no difference in age between those
who rejected (8.8 ± 0.4 years, N = 11) or accepted (8.7 ±
0.3 years, N = 23) them (F(1,32) = 0.027; p = 0.87). More
than half of these children were trained to take pills
(58.8 %; N = 20/34), as reported by their mothers. One-
third of these children (35 %; N = 7/20) had problems
swallowing or rejected the pills despite training. While
this small sample size precludes statistical conclusions,
we found that 75 % (15/20) of children with at least one
bitter-sensitive allele (AP/PP) reported having taken a
solid formulation compared to 57 % (8/14) of children
with no bitter-sensitive alleles (AA).
Discussion
Based on prior results that variation in a bitter taste
receptor gene, TAS2R38, was related to solid (pill) for-
mulation usage [17], we interviewed children and their
mothers separately and included questions about liquid
formulation usage and memories of past experiences
with medicines, and then determined if children’s re-
sponses were related to their TAS2R38 genotype and
with responses of their mothers. Mothers reported
having problems administering all types of oral for-
mulations to their children, and they and their chil-
dren reported rejecting medications primarily for “taste”
reasons. However, not all children (especially those <4 years
old) responded to open-ended questions regarding past use
of medication, highlighting limitations in collecting such in-
formation in this manner from younger children. Consist-
ent with prior reports [10, 22–24], liquid formulations were
preferred by mothers but were most reported by children
as being problematic to take. Such findings reflect chil-
dren’s biology: research on children of the age range in
the present study (3–10 years) has repeatedly revealed
that they reject bitter tastes [13, 15, 16] and avoid un-
pleasant flavors and textures [2] but favor sweet (pleasant)
tastes [18, 25, 26]. The child’s most preferred levels of
sweetness and sensitivity to bitterness do not go through
pronounced changes until mid-adolescence, achieving
levels measured in adults [16, 26].
Some mothers attempted to train their children to
swallow pills, with only moderate success. Some children
voiced concerns about taking pills and fear of choking
[27]. Children who had successfully taken a solid dosage
form averaged 9 years of age, a finding remarkably consist-
ent with data derived from pharmacy dispensing records
in the Netherlands [4]. Like teenagers and adults, older
children vary greatly in biomechanics of swallowing
and ability to swallow tablets and capsules [1], despite
behavioral training [27, 28]. Therefore, offering medi-
cines in pill form to children is only partially successful
even for older children.
Table 3 Reasons given by children for refusing medications
Taste/flavor, 84.9 % (73/86)
“Nasty”/“Nasty taste” (n = 32) “Doesn’t taste good”
“Yucky” (n = 4) “Taste like fish”
“Bitter” (n = 3) “Don’t like grape”
“Tastes horrible” (n = 2) “Sour/salty taste”
“Gross/tastes gross” (n = 2) “Bitter cherry/ear wax taste”
“Tastes ugh” (n = 2) “Doesn’t taste like cranberries”
“Bad taste” (n = 2) “Only like blueberries”
“Icky taste later” “Fruit flavor, only bubble gum flavors”
“Nasty after taste” “Tastes nasty, only like bubble gum”
“Tastes old” “Nasty, doesn’t like cherry”
“Tastes like poison” “Tastes nasty/doesn’t like color or flavor”
“Don’t like taste” “Too hard”
“They have vegetables inside
and don’t taste good”
“Mom puts it in salty water”
“Tastes like alcohol” “Tastes like salt water”
“Tastes like diet” “Tasted horrible and scared to swallow”
“Hated taste” “Tastes too sour, old people like them”
“Disgusting”
Problems with swallowing or
choking, 8.1 % (7/86)
“Hard to swallow” (n = 2) “Scared to choke”
“Couldn’t swallow and
choked on it”
“Have to drink water to swallow them”
“Gag, can’t chew, hard to
swallow”
“Afraid because little boy on TV choked
from pills”
Consequences of taking
medicine, 2.3 % (2/86)
“Allergic” “Makes me have headaches”
Combination/other, 4.7 % (4/86)
“I don’t know” (n = 2) “I don’t know what to do with them”
“Medicine is for grownups”
Responses are n = 1, except as noted
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Not only are some children more sensitive to bitter
tastes than are adults despite similar genetics [15, 16], but
we found that some children were genetically more sensi-
tive than others, and such differences are related to liquid
medication usage and acceptance. In the present study,
children who had at least one sensitive allele (PP or AP) of
the bitter taste receptor gene TAS2R38 were more likely
to report rejecting liquid medications than were children
with the insensitive (AA) allele, extending our previous
findings that this taste genotype is associated with ex-
perience of solid medicine formulations [17]. Unlike
this prior study where many of the 3- to 10-year-old
children (N = 138) had taken medicine in solid form
[17], few children (N = 34) in the present study had
done so. Nevertheless, we have observed the relation-
ship between TAS2R38 genotype and issues related to
medications in two independent populations of children
([17]; present study). Although the TAS2R38 receptor
gene is unlikely to be sensitive to all bitter compounds
found in medications, its alleles may be a proxy for
general taste ability [29], are related to acceptance of other
bitters such as those found in vegetables [30] and are asso-
ciated with individual differences in other aspects of taste
biology (e.g., sweet preference) [13]. Also, because bitter
taste receptor genes occur in linked clusters [31], genetic
variation in this receptor may be related to variation in
other receptors. Future work should also relate variation
in medication acceptance among children to polymorph-
ism of other taste receptor genes, including those related
to sweet taste.
The present study focused on children’s and mothers’
reports of past experiences with medications, rather
than assessing taste rejection or actual compliance with
a specific medication. While not all children can pro-
vide information on the sensory acceptance of medica-
tions, we found concordance between reports by children
and their mothers regarding medication usage, indicating
both the ability of children to report on their own experi-
ences and the reliability of their mother’s reports for
children who are not able to respond themselves. Chil-
dren’s perceptions, as well as those of their caregivers, are
valuable and, as illustrated herein, highlight the formidable
task faced by health professionals and parents to provide
oral dosage formulations that children like or accept its
taste. An estimated 40 % of the world’s children are at
increased risk for avoidable adverse events such as sub-
optimal dosing and lack of adherence to medication regi-
mens [3, 10, 32]. How much suboptimal dosing arises
solely from the bad taste of medicine is unknown, but
these data suggest that prospective studies are needed
to understand the role of individual differences in taste
acceptance of individual medicines. Our data point to-
ward the feasibility of gathering such information from
children and, for very young children, from their mothers
regarding experiences with medications. However, it is
important to note that for foods, mothers are more ac-
curate in the types of foods that are disliked by their
children than those that are liked [33]. Thus, it may be
if one is interested in children's dislikes of particular
medicines, maternal reports might be suitable but if
one is interested in their likes, applying age-appropriate
sensory methodologies rather than maternal reports
may be more appropriate [2].
Future pediatric clinical trials thus could systematic-
ally collect data regarding taste acceptance/palatability
of particular medicines directly from children and their
caregivers (see [11]). Such data, combined with informa-
tion on the type of formulation, types of excipients, and
methods of administration [34], will help develop and val-
idate nonproprietary methods to assess behaviors associ-
ated with concepts such as “acceptance”, “rejection” and
“palatability”. These methods need to be sensitive to the
cognitive limitations of children of varying ages (see
ref. [2] for discussion). The ultimate goal is to develop
well-accepted pediatric formulations that effectively treat
illnesses for all children.
Conclusions
In this study, children reported rejecting medication
primarily because of taste complaints, and those with
at least one sensitive TAS2R38 allele (AP or PP genotype)
were more likely to report rejecting liquid medications
than those without a taster allele. Thus, individual differ-
ences in taste responses to medications highlight the need
to consider children’s genetic variation and their own per-
ceptions when developing formulations acceptable to the
pediatric palate. Mothers’ and children’s reports of chil-
dren’s past problems with medication matched, indicating
that pediatric trials could systematically collect information
directly from either children or their caregivers regarding
issues related to acceptance or rejection of medicines, pro-
viding data to develop well-accepted pediatric formulations
that effectively treat illnesses for all children.
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